Immune-Enriched Versus Matrix-Remodeling Microenvironments in Psammoma Body-Rich and Psammoma Body-Poor WHO Grade I

Tahreem Fatima1,2

  • 1Cooperative Trials Group for Neuro-Oncology (COGNO), Sydney, Australia.

Insights

Psammoma bodies in meningiomas may indicate a chronically inflamed tumor microenvironment. This study reveals distinct molecular pathways in psammoma body-rich versus psammoma body-poor tumors, linking inflammation to calcification.

Area of Science:

  • Neuropathology
  • Molecular Biology
  • Immunology

Background:

  • Psammoma bodies are calcifications in WHO grade I meningiomas.
  • Their abundant formation in specific subtypes remains unexplained.
  • Current theories suggest passive calcification, but active processes are also proposed.

Purpose of the Study:

  • To investigate the molecular differences between psammoma body-rich (PB-rich) and psammoma body-poor (PB-poor) WHO grade I meningiomas.
  • To explore the potential link between psammoma body formation and tumor microenvironment.
  • To identify molecular pathways associated with psammoma body presence.

Main Methods:

  • Differential gene expression analysis of a public dataset (GSE43290) comparing PB-rich and PB-poor meningiomas.
  • Functional enrichment analysis using GEO2R and g:Profiler.
  • Identification of core genes and associated pathways for each subtype.

Main Results:

  • PB-rich tumors showed enrichment in immune/inflammatory pathways, including chemokine signaling and Toll-like receptor cascades.
  • PB-poor tumors were characterized by extracellular matrix remodeling and collagen organization.
  • PB-rich core genes linked to NK-cell and cytotoxic T-cell activity, while PB-poor genes associated with stromal pathways.

Conclusions:

  • Psammoma body formation may be a morphological marker of a chronically inflamed tumor microenvironment.
  • Findings support a mechanistic framework linking immune activation to calcification in meningiomas.
  • Identified candidate pathways and genes warrant further investigation for therapeutic targets.